Comparison between microwave ablation and uterine artery embolization for treating symptomatic uterine fibroids
Xiao Liang Lin1, Li Yan Guo2, Xue Juan Dong1, Zhi Yu Han1, Jie Yu1, Ping Liang1, Rui Liu3, Yong Jin2*, Jing Zhang *
ABSTRACT
Objectives: To retrospectively compare the effectiveness, safety, and economy of microwave ablation (MWA) and uterine artery embolization (UAE) for treating symptomatic uterine fibroids (UFs).
Methods: 174 women with symptomatic UFs who met the inclusion and exclusion criteria were enrolled in this retrospective study from April 2010 to November 2019. 89 patients underwent MWA, and 85 patients underwent UAE. All patients were followed up for 12 months. Assessment parameters included regression of uterine and fibroid volume, symptom severity scale (SSS), health-related quality of life score (HQOL), dysmenorrhea scores, improvement of anemia, adverse events (AEs), length of hospital stay and cost.
Results: After treatment, uterine and fibroid volumes in two groups were demonstrably smaller than those of baseline, and there was no significant difference in uterine volume between the two groups. The volume of fibroids in MWA group was significantly smaller than that in UAE group during the 3 follow-up months, and there was no significant difference in other periods. HRQL was higher than baseline, while SSS and VAS were remarkably lower than baseline. There were no significant difference in HRQL, SSS, VAS between the two groups. The hemoglobin levels in both groups of patients with anemia were demonstrably higher in the posttreatment than before treatment. During the follow-up 3 months, the hemoglobin level in MWA group was significantly improved compared with that in UAE group. There was no significant difference in additional intervention after treatment between MWA and UAE. Comparison of AEs, abdominal pain score, the number of postoperative vaginal secretion and amenorrhea in the MWA group was significantly lower than that in the UAE group. But UAE showed shorter hospitalization, and lower cost to MWA (all p < 0.001).